Hua Ren Pharmaceutical Company: The company and its subsidiaries are selected by inter-provincial alliance for centralized procurement.

Hua Ren Pharmaceutical announced on the evening of June 3 that the company and its wholly-owned subsidiary Hua Ren Pharmaceutical Co., Ltd. recently participated in the bidding for the inter-provincial alliance bulk purchasing of 66 chemical drugs such as cyclophosphamide and glucosamine. According to the selection results recently announced by the Sichuan Provincial Pharmaceutical Equipment Bidding and Purchasing Service Center, the company's product blood filtration replacement basic solution, isosorbide mononitrate sodium chloride injection, and its subsidiary Hua Ren Pharmaceutical Co., Ltd.'s products mannitol injection, and carotane sodium chloride injection were selected for this round of bulk purchasing. The total sales revenue of the selected products in 2024 is 85.6177 million yuan, accounting for 6.33% of the company's total operating income in 2024.